Maureen Cleary1,2, James Davison3,4, Rachel Gould5, Tarekegn Geberhiwot6, Derralynn Hughes7, Jean Mercer8, Alexandra Morrison9, Elaine Murphy10, Saikat Santra5, James Jarrett11, Swati Mukherjee11, Karolina M Stepien12. 1. Department of Metabolic Medicine, Great Ormond Street Hospital, Great Ormond St., London, WC1N 3JH, UK. maureen.cleary@gosh.nhs.uk. 2. NIHR Biomedical Research Centre London, London, UK. maureen.cleary@gosh.nhs.uk. 3. Department of Metabolic Medicine, Great Ormond Street Hospital, Great Ormond St., London, WC1N 3JH, UK. 4. NIHR Biomedical Research Centre London, London, UK. 5. Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK. 6. University Hospital Birmingham, Birmingham, UK. 7. Royal Free NHS Foundation Trust and University College London, London, UK. 8. Saint Mary's Hospital, Manchester, UK. 9. Rare Disease Research Partners, Amersham, UK. 10. National Hospital for Neurology and Neurosurgery, London, UK. 11. BioMarin International Ltd., London, UK. 12. Salford Royal NHS Foundation Trust, Salford, UK.
Abstract
BACKGROUND: We present baseline characteristics and follow-up data of a Managed Access Agreement (MAA), including patients with mucopolysaccharidosis IVA (MPS IVA) receiving elosulfase alfa enzyme replacement therapy (ERT) in England on a conditional basis. Patients enrolled in the MAA programme are reviewed on an annual basis. Therapy can be continued if patients are compliant, able to tolerate infusions, and meet four out of five pre-defined clinical and patient-reported outcomes (PRO) criteria. Baseline and follow-up clinical and PRO data are presented for all participants who completed ≥ 1 year of assessments in the MAA. RESULTS: The analysis included data from 55 patients, including 26 patients previously enrolled in clinical trials and 29 who started ERT after enrolling in the MAA. In patients with both baseline and follow-up data, mean 6-min walk test distance increased from 217 m at baseline to 244 m after a mean follow-up of 4.9 years. Improvement or stabilisation was seen regardless of age at treatment initiation or duration of treatment. Mean forced vital capacity and forced expiratory volume in 1 s were 0.87 L and 0.78 L, respectively at baseline and 1.05 L and 0.88 L after a mean follow-up of 5.5 years. PRO data showed overall improvements over time in Mobility, Self-care, and Caregiver assistance scores of the MPS-Health Assessment Questionnaire, relatively stable quality of life, and some improvements in pain scores. CONCLUSIONS: The MAA data confirm the effects of elosulfase alfa on clinical and PRO results observed in the clinical trials and provide real-world evidence for long-term stabilisation in these measures, suggesting a positive impact on the natural history of MPS IVA.
BACKGROUND: We present baseline characteristics and follow-up data of a Managed Access Agreement (MAA), including patients with mucopolysaccharidosis IVA (MPS IVA) receiving elosulfase alfa enzyme replacement therapy (ERT) in England on a conditional basis. Patients enrolled in the MAA programme are reviewed on an annual basis. Therapy can be continued if patients are compliant, able to tolerate infusions, and meet four out of five pre-defined clinical and patient-reported outcomes (PRO) criteria. Baseline and follow-up clinical and PRO data are presented for all participants who completed ≥ 1 year of assessments in the MAA. RESULTS: The analysis included data from 55 patients, including 26 patients previously enrolled in clinical trials and 29 who started ERT after enrolling in the MAA. In patients with both baseline and follow-up data, mean 6-min walk test distance increased from 217 m at baseline to 244 m after a mean follow-up of 4.9 years. Improvement or stabilisation was seen regardless of age at treatment initiation or duration of treatment. Mean forced vital capacity and forced expiratory volume in 1 s were 0.87 L and 0.78 L, respectively at baseline and 1.05 L and 0.88 L after a mean follow-up of 5.5 years. PRO data showed overall improvements over time in Mobility, Self-care, and Caregiver assistance scores of the MPS-Health Assessment Questionnaire, relatively stable quality of life, and some improvements in pain scores. CONCLUSIONS: The MAA data confirm the effects of elosulfase alfa on clinical and PRO results observed in the clinical trials and provide real-world evidence for long-term stabilisation in these measures, suggesting a positive impact on the natural history of MPS IVA.
Authors: Paul R Harmatz; Karl Eugen Mengel; Roberto Giugliani; Vassili Valayannopoulos; Shuan-Pei Lin; Rossella Parini; Nathalie Guffon; Barbara K Burton; Christian J Hendriksz; John J Mitchell; Ana Maria Martins; Simon A Jones; Norberto Guelbert; Ashok Vellodi; Frits A Wijburg; Ke Yang; Peter Slasor; Celeste Decker Journal: Mol Genet Metab Date: 2014-11-01 Impact factor: 4.797
Authors: Christian J Hendriksz; Rossella Parini; Moeenaldeen D AlSayed; Julian Raiman; Roberto Giugliani; Martha L Solano Villarreal; John J Mitchell; Barbara K Burton; Norberto Guelbert; Fiona Stewart; Derralynn A Hughes; Kenneth I Berger; Peter Slasor; Robert Matousek; Elaina Jurecki; Adam J Shaywitz; Paul R Harmatz Journal: Mol Genet Metab Date: 2016-06-16 Impact factor: 4.797
Authors: Becky Schweighardt; Troy Tompkins; Kelly Lau; Lynne Jesaitis; Yulan Qi; Donald G Musson; Pamela Farmer; Christine Haller; Adam J Shaywitz; Ke Yang; Charles A O'Neill Journal: Clin Ther Date: 2014-12-06 Impact factor: 3.393
Authors: Christian J Hendriksz; Rossella Parini; Moeenaldeen D AlSayed; Julian Raiman; Roberto Giugliani; John J Mitchell; Barbara K Burton; Norberto Guelbert; Fiona J Stewart; Derralynn A Hughes; Robert Matousek; Sara M Hawley; Celeste Decker; Paul R Harmatz Journal: Mol Genet Metab Date: 2017-12-05 Impact factor: 4.797
Authors: C J Hendriksz; P Harmatz; M Beck; S Jones; T Wood; R Lachman; C G Gravance; T Orii; S Tomatsu Journal: Mol Genet Metab Date: 2013-04-10 Impact factor: 4.797
Authors: Barbara K Burton; Kenneth I Berger; Gregory D Lewis; Mark Tarnopolsky; Marsha Treadwell; John J Mitchell; Nicole Muschol; Simon A Jones; V Reid Sutton; Gregory M Pastores; Heather Lau; Rebecca Sparkes; Fred Genter; Adam J Shaywitz; Paul Harmatz Journal: Am J Med Genet A Date: 2015-06-10 Impact factor: 2.802
Authors: Paul R Harmatz; Eugen Mengel; Tarekegn Geberhiwot; Nicole Muschol; Christian J Hendriksz; Barbara K Burton; Elisabeth Jameson; Kenneth I Berger; Andrea Jester; Marsha Treadwell; Zlatko Sisic; Celeste Decker Journal: Am J Med Genet A Date: 2016-10-24 Impact factor: 2.802
Authors: Christian J Hendriksz; Barbara Burton; Thomas R Fleming; Paul Harmatz; Derralynn Hughes; Simon A Jones; Shuan-Pei Lin; Eugen Mengel; Maurizio Scarpa; Vassili Valayannopoulos; Roberto Giugliani; Peter Slasor; Debra Lounsbury; Wolfgang Dummer Journal: J Inherit Metab Dis Date: 2014-05-09 Impact factor: 4.982